Laboratory assessment of rivaroxaban: a review

Thrombosis Journal

Jean-Luc Martinoli¹  Gabriele Rohde²  Yves Gourmelin¹  Céline Guinet³  Lena Le Flem³  Elisabeth Perzborn²  Theodore E Spiro⁴  Geneviève Contant¹  Meyer Michel Samama³ 

[1] Diagnostica Stago SA, 125 avenue Louis Roche, P.A.E. Parispace 3, 92230 Gennevilliers, France;Bayer HealthCare AG, Aprather Weg 18a, D-42096 Wuppertal, Germany;Biomnis Laboratories R & D, 78 avenue de Verdun, BP 110,94200 Ivry-sur-Seine, Paris, France;Bayer HealthCare Pharmaceuticals Inc., PO Box 1000, 07045-1000 Montville, NJ, USA

关键词: Rivaroxaban;    Laboratory assessment;    Factor Xa;   

Others  :  838582
DOI  :  10.1186/1477-9560-11-11

 received in 2013-03-01, accepted in 2013-06-24,  发布年份 2013

【 摘 要 】

Research into new anticoagulants for preventing and treating thromboembolic disorders has focused on targeting single enzymes in the coagulation cascade, particularly Factor Xa and thrombin, inhibition of which greatly decreases thrombin generation. Based on the results of phase III clinical trials, rivaroxaban, a direct Factor Xa inhibitor, has been approved in many countries for the management of several thromboembolic disorders. Owing to its predictable pharmacokinetic and pharmacodynamic characteristics, fixed-dose regimens are used without the need for routine coagulation monitoring. In situations where assessment of rivaroxaban exposure may be helpful, anti-Factor Xa chromogenic assays (in tandem with standard calibration curves generated with the use of rivaroxaban calibrators and controls) could be used. It is important to note that test results will be affected by the timing of blood sampling after rivaroxaban intake. In addition, the anti-Factor Xa method measures the drug concentration and not the intensity of the drug’s anticoagulant activity, and a higher than expected rivaroxaban plasma level does not necessarily indicate an increased risk of bleeding complications. Therefore, clinicians need to consider test results in relation to the pharmacokinetics of rivaroxaban and other patient risk factors associated with bleeding.

【 授权许可】

   
2013 Samama et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G: Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141:e44S-e88S.
• [2]Garcia DA, Baglin TP, Weitz JI, Samama MM: Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141:e24S-e43S.
• [3]Bayer Pharma AG: Xarelto® (rivaroxaban) summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf webcite
• [4]Janssen Pharmaceuticals Inc: Xarelto® (rivaroxaban) prescribing information. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022406s004lbl.pdf webcite
• [5]Boehringer Ingelheim International GmbH: Pradaxa® (dabigatran etexilate) summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf webcite
• [6]Boehringer Ingelheim Pharmaceuticals Inc: Pradaxa® (dabigatran etexilate) prescribing iInformation. 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022512s016lbl.pdf webcite
• [7]Bristol-Myers Squibb, Pfizer EEIG: Eliquis® (apixaban) summary of product characteristics. 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf webcite
• [8]Bristol-Myers Squibb Company, Pfizer Inc: Eliquis® (apixaban) prescribing information. 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf webcite
• [9]Committee for Medicinal Products for Human Use: Summary of opinion (post authorisation): Xarelto, rivaroxaban. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000944/WC500140679.pdf webcite
• [10]Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP: Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993, 91:1877-1883.
• [11]Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990, 86:385-391.
• [12]Eriksson BI, Quinlan DJ, Eikelboom JW: Novel oral Factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med 2011, 62:41-57.
• [13]Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A: In vitro and in vivo studies of the novel antithrombotic agent BAY 59–7939– an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005, 3:514-521.
• [14]Samama MM, Guinet C: Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011, 49:761-772.
• [15]Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G: Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59–7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Ther 2005, 78:412-421.
• [16]Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F: The discovery and development of rivaroxaban, an oral, direct Factor Xa inhibitor. Nat Rev Drug Discov 2011, 10:61-75.
• [17]Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, Gent M, Haas S, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AGG: Population pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct Factor Xa inhibitor – in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008, 47:203-216.
• [18]Xu XS, Moore K, Burton P, Stuyckens K, Mueck W, Rossenu S, Plotnikov A, Gibson M, Vermeulen A: Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. Br J Clin Pharmacol 2012, 74:86-97.
• [19]Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F: Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011, 50:675-686.
• [20]Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M: Safety, pharmacodynamics, and pharmacokinetics of BAY 59–7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005, 61:873-880.
• [21]Kubitza D, Becka M, Roth A, Mueck W: Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008, 24:2757-2765.
• [22]Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D: Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans. Drug Metab Dispos 2009, 37:1056-1064.
• [23]Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M: Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct Factor Xa inhibitor-in healthy subjects. Int J Clin Pharmacol Ther 2007, 45:335-344.
• [24]Samama MM, Martinoli JL, Le Flem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E: Assessment of laboratory assays to measure rivaroxaban – an oral, direct Factor Xa inhibitor. Thromb Haemost 2010, 103:815-825.
• [25]Barrett YC, Wang Z, Frost C, Shenker A: Clinical laboratory measurement of direct Factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010, 104:1263-1271.
• [26]Harenberg J, Marx S, Weiss C, Kramer R, Samama M, Schulman S: Report of the subcommittee of control of anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost 2012, 10:1433-1436.
• [27]Sekisui Diagnostics LLC: HepTest. Clotting procedures for the quantitative determination of heparin in plasma and whole blood. 2009. https://americandiagnostica.com/wp-content/uploads/2011/12/830.pdf webcite
• [28]Harder S, Parisius J, Picard-Willems B: Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): Relation to FXa-activity and influence of assay modifications. Thromb Res 2008, 123:396-403.
• [29]Graff J, Von Hentig N, Misselwitz F, Kubitza D, Becka M, Breddin HK, Harder S: Effects of the oral, direct Factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007, 47:1398-1407.
• [30]Gerotziafas GT, Elalamy I, Depasse F, Perzborn E, Samama MM: In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct Factor Xa inhibitor rivaroxaban. J Thromb Haemost 2007, 5:886-888.
• [31]Samama MM, Amiral J, Guinet C, Perzborn E, Depasse F: An optimised, rapid chromogenic assay, specific for measuring direct Factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost 2010, 104:1078-1079.
• [32]Harenberg J, Kramer R, Giese C, Marx S, Weiss C, Wehling M: Determination of rivaroxaban by different Factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombolysis 2011, 32:267-271.
• [33]Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, Le Flem L, Rohde G, Martinoli JL: Evaluation of the anti-Factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012, 107:379-387.
• [34]Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE: Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 2010, 32:673-679.
• [35]Smith SA, Comp PC, Morrissey JH: Phospholipid composition controls thromboplastin sensitivity to individual clotting factors. J Thromb Haemost 2006, 4:820-827.
• [36]Smith SA, Morrissey JH: Thromboplastin composition affects the sensitivity of prothrombin time (PT) clotting tests to direct Factor Xa inhibitors. [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 928.
• [37]Siegal DM, Crowther MA: Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J 2013, 34:489-498.
• [38]Tripodi A, Chantarangkul V, Guinet C, Samama MM: The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost 2011, 9:226-228.
• [39]Kluft C: A large effects of rivaroxaban in the PT with specifically Simplastin Excel S may be used for diagnostic purposes [abstract]. Hämostaseologie 2012, 32:A83. Abstract P6-40
• [40]Samama MM, Contant G, Spiro TE, Perzborn E, Le Flem L, Guinet C, Gourmelin Y, Martinoli JL: Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost 2012, 18:150-158.
• [41]Kies MS, Posch JJ Jr, Giolma JP, Rubin RN: Hemostatic function in cancer patients. Cancer 1980, 46:831-837.
• [42]Seifter EJ, Parker RI, Gralnick HR, Wesley M, DeVita VT Jr, Young RC, Longo DL: Abnormal coagulation results in patients with Hodgkin's disease. Am J Med 1985, 78:942-950.
• [43]Thachil J: Relevance of clotting tests in liver disease. Postgrad Med J 2008, 84:177-181.
• [44]Mani H, Rohde G, Stratmann G, Hesse C, Herth N, Schwers S, Perzborn E, Lindhoff-Last E: Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost 2012, 108:191-198.
• [45]Asmis LM, Alberio L, Angelillo-Scherrer A, Korte W, Mendez A, Reber G, Seifert B, Stricker H, Tsakiris DA, Wuillemin WA: Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res 2012, 129:492-498.
• [46]Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kälebo P, Muelhofer E, Misselwitz F, Eriksson BI: Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008, 100:453-461.
• [47]Eikelboom JW, Weitz JI: New anticoagulants. Circulation 2010, 121:1523-1532.
• [48]Bounameaux H, Reber G: New oral antithrombotics: a need for laboratory monitoring. Against. J Thromb Haemost 2010, 8:627-630.
• [49]Harenberg J, Du S, Kramer S, Giese C, Schulze A, Weiss C, Kramer R: Novel methods for assessing oral direct factor Xa and thrombin inhibitors: use of point-of-care testing and urine samples. Semin Thromb Hemost 2013, 39:66-71.
• [50]Schulman S, Crowther MA: How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood 2012, 119:3016-3023.
• [51]Ortel TL: Perioperative management of patients on chronic antithrombotic therapy. Blood 2012, 120:4699-4705.
• [52]Turpie AGG, Kreutz R, Llau J, Norrving B, Haas S: Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor. Thromb Haemost 2012, 108:876-886.
• [53]Huisman MV, Lip GYH, Diener HC, Brueckmann M, van Ryn J, Clemens A: Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012, 107:838-847.